Key result
Aortic valve stenosis induces swirling blood flow causing subclinical hemolysis and cell-free hemoglobin release, which impairs NO bioavailability and promotes reversible endothelial dysfunction.
Why the study?
The impact of aortic valve stenosis on systemic endothelial function independent of standard modifiable risk factors was unknown.
Does TAVR or haptoglobin infusion improve endothelial function and NO bioavailability in aortic valve stenosis?
Observational (n=1,584)
Does TAVR or haptoglobin infusion improve endothelial function and NO bioavailability in aortic valve stenosis?
p-value: p=<0.0001
Aortic valve stenosis independently promotes systemic endothelial dysfunction through subclinical hemolysis and NO scavenging, an effect that can be reversed by TAVR.
Highlights potential fHb-mediated endothelial effects in AS; leaves open targeted interventions pending validation.
Rationale The impact of aortic valve stenosis (AS) on systemic endothelial function independent of standard modifiable risk factors (SMuRFs) is unknown. Objective We hypothesized that AS induces subclinical hemoglobin release from red blood cells (RBCs) following transvalvular passage due to post-stenotic aberrant blood flow and that cell-free hemoglobin (fHb) may limit endothelial NO bioavailability, affecting vascular function. Methods and Results AS induces swirling blood flow in the ascending aorta which impairs RBC integrity with consecutive release of fHb. Indeed, swirl flow magnitude assessed by 4D flow cardiac magnetic resonance correlates with fHb levels. Elevated systemic fHb reduces NO bioavailability and thus impairs endothelial cell function as evidenced by impaired flow mediated dilation (FMD). In addition, we here demonstrate impaired FMD in an experimental model of AS utilising C57BL/6 mice with preserved left ventricular function and without cardiovascular risk factors. In this model, endothelial dysfunction is accompanied by significantly increased fHb, exaggerated NO consumption and increased plasma levels of nitroso species and the final NO oxidation product, nitrate. Scavenging of fHb by infusion of haptoglobin reversed these deleterious effects. There observations were verified by transfer experiments with human plasma (sampled from patients with AS sheduled for TAVR) using a murine aortic ring bioassay system where the plasma from AS patients induced endothelial dysfunction when compared to plasma from control individuals without AS. Importantly, these deleterious effects were reversed by successful aortic valve replacement via TAVR independent of SMuRFs. Conclusions In aortic valve stenosis, increases in post-valvular swirl blood flow in the ascending aorta induces subclinical hemolysis that impairs NO bioavailability. Thus, AS itself promotes systemic endothelial dysfunction independent of other established risk factors. Transcatheter aortic valve replacement limits NO scavenging by realigning of postvalvular blood flow to normal physiological patterns.
No takes yet. Share an insight, caveat, or question.
Quast et al. (2022) conducted an observational in Aortic valve stenosis (n=1,584). Aortic valve stenosis vs. Age- and comorbidity-matched controls without aortic valve stenosis was evaluated on Correlation between peak velocity in the ascending aorta and cell-free hemoglobin levels (95% CI 0.5292-0.9219, p=<0.0001). Aortic valve stenosis induces swirling blood flow causing subclinical hemolysis and cell-free hemoglobin release, which impairs NO bioavailability and promotes reversible endothelial dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: